GDF-15 Blockade Overcomes Resistance to Immune Checkpoint Inhibition

Main Findings: Visugromab, a GDF-15 blocking antibody, is tolerable and elicits clinical responses in combination with nivolumab.Concept: GDF-15 may represent a mechanism of anti-PD-1 resistance that can be targeted to enhance antitumor immunity.Impact: This phase I/IIa trial supports the safety and further clinical evaluation of this combination, particularly in NSCLC and urothelial cancer.

Publication Details

Journal: Cancer Discovery
Published: 2025-01-01
DOI: https://doi.org/10.1158/2159-8290.cd-rw2025-001
Primary Topic: GDF15 and Related Biomarkers
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

GDF-15 Blockade Overcomes Resistance to Immune Checkpoint Inhibition

Jan 1, 2025

Cancer Discovery

GDF15 and Related Biomarkers

article

GDF-15 Blockade Overcomes Resistance to Immune Checkpoint Inhibition

January 1, 2025article en

Abstract

Cancer Discovery

Zero hunger

Openalex Percentile: Top 99%

GDF15 and Related Biomarkers

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

GDF-15 Blockade Overcomes Resistance to Immune Checkpoint Inhibition · Cancer Discovery (2025) | TGRS Research Map | TGRS